Ann: Lumos receives CPT PLA Code for FebriDX in the US, page-26

Some communication with IR from last year around margin levels with diagnostics (general diagnostics space) would place it like this:

Provider buys Febridx for $25 per test. From the $41 reimbursement rate, the provider make back the cost of the test plus the difference to incentivise use of the test. Provider makes $16 profit per use of the test.

LDX sells the test for $25 and has a profit margin built into the retail price. Wholesale is typically 60% of the retail price which would make it $15 wholesale. I think somewhere LDX indicated a 50% profit margin? So likely $7.50 per test?

This would likely also be the way we work out the potential FFN annuity. Look at 10% of overall annual sale price for the FFN test specifically for a manufacturer margin.